Literature DB >> 16953835

Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B.

Chun-Jen Liu1, Pei-Jer Chen, Ming-Yang Lai, Feng-Yi Lin, Tzusan Wang, Jia-Horng Kao, Ding-Shinn Chen.   

Abstract

BACKGROUND/AIMS: Seroconversion (SC) from hepatitis B envelope antigen (HBeAg) to anti-HBe usually indicates lower viral loads, resolved hepatitis activity and improved long-term outcomes. However, the role of viral factors in the development of SC remains largely unknown. We thus comprehensively studied these factors in 25 patients with sustained HBeAg SC and seven control patients with sustained loss of HBeAg.
METHODS: We determined viral factors in serum samples obtained 1 year before, 6 months before, 3 months before, at the time of, 6 months after and 1 year after HBeAg SC or HBeAg loss. Precore A1896 and basal core promoter T1762/A1764 mutants were determined by polymerase chain reaction (PCR)-based assays. Serum HBV levels were determined by a real-time PCR assay.
RESULTS: We found that decline of serum viral load, frequently accompanied by hepatitis exacerbation, occurred within 1 year before HBeAg SC. The proportions of precore and BCP mutations also increased gradually throughout the process of HBeAg SC. The virologic features were similar between HBeAg SC group and HBeAg loss group. Before HBeAg SC or loss, genotype B patients had higher serum viral loads and lower proportions of BCP mutation compared with genotype C patients.
CONCLUSION: Our findings suggested that viral factors correlate with the development of sustained HBeAg SC or loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953835     DOI: 10.1111/j.1478-3231.2006.01319.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Performance evaluation of TRUPCR® HBV Real-time PCR assay for Hepatitis B virus DNA quantification in clinical samples: report from a tertiary care liver centre.

Authors:  Sujata Lall; Manish C Choudhary; Supriya Mahajan; Guresh Kumar; Ekta Gupta
Journal:  Virusdisease       Date:  2019-01-05

Review 2.  Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome.

Authors:  Young Min Park
Journal:  World J Hepatol       Date:  2015-01-27

3.  The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up.

Authors:  Tsung-Hui Hu; Ming-Chao Tsai; Yen-Ta Chen; Yu-Shu Chien; Chao-Hung Hung; Te-Chuan Chen; Po-Lin Tseng; Kuo-Chin Chang; Yi-Hao Yen
Journal:  Hepatol Int       Date:  2011-07-12       Impact factor: 6.047

4.  HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2009-06-24       Impact factor: 6.047

5.  Role of viral factors in the natural course and therapy of chronic hepatitis B.

Authors:  Jia-Horng Kao
Journal:  Hepatol Int       Date:  2007-10-12       Impact factor: 6.047

Review 6.  Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Mol Biol Rep       Date:  2020-12-09       Impact factor: 2.316

7.  Comparison of real-time polymerase chain reaction with the COBAS Amplicor test for quantitation of hepatitis B virus DNA in serum samples.

Authors:  Ming Shi; Yong Zhang; Ying-Hua Zhu; Jing Zhang; Wei-Jia Xu
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Xue-Yan Wang; Tim J Harrison
Journal:  J Hepatol       Date:  2008-11-14       Impact factor: 25.083

9.  Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients.

Authors:  Linlin Yan; Henghui Zhang; Hui Ma; Di Liu; Wei Li; Yulin Kang; Ruifeng Yang; Jianghua Wang; Gaixia He; Xingwang Xie; Hao Wang; Lai Wei; Zuhong Lu; Qixiang Shao; Hongsong Chen
Journal:  Sci Rep       Date:  2015-12-09       Impact factor: 4.379

10.  Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial.

Authors:  Jinsong He; Daqiao Zhou; Guangdong Tong; Yufeng Xing; Yingjie Chen; Xiaohui Zhang; Bolin Zhan; Hui Gao; Xiaozhou Zhou; Yiqun Xiong; Xinliang Liu; Lisheng Peng; Mei Qiu; Yingjun Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.